Tempest Therapeutics (TPST) to Release Quarterly Earnings on Tuesday

Tempest Therapeutics (NASDAQ:TPST) is projected to issue its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Tempest Therapeutics (NASDAQ:TPST) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.62) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.62). On average, analysts expect Tempest Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tempest Therapeutics Trading Down 1.7%

Shares of TPST stock traded down $0.04 on Tuesday, hitting $2.08. The stock had a trading volume of 45,397 shares, compared to its average volume of 179,146. Tempest Therapeutics has a twelve month low of $1.50 and a twelve month high of $12.23. The firm has a market cap of $29.76 million, a P/E ratio of -0.32 and a beta of -1.75. The company has a fifty day moving average price of $2.01 and a two-hundred day moving average price of $3.84.

Analysts Set New Price Targets

TPST has been the subject of several research analyst reports. Wall Street Zen raised shares of Tempest Therapeutics to a “hold” rating in a report on Saturday, April 18th. Zacks Research raised shares of Tempest Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 2nd. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy”.

Insider Buying and Selling

In other Tempest Therapeutics news, CEO Matthew Angel purchased 231,482 shares of the business’s stock in a transaction on Tuesday, March 24th. The shares were purchased at an average cost of $2.16 per share, with a total value of $500,001.12. Following the transaction, the chief executive officer directly owned 231,482 shares of the company’s stock, valued at $500,001.12. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.28% of the stock is owned by company insiders.

Institutional Investors Weigh In On Tempest Therapeutics

A hedge fund recently bought a new stake in Tempest Therapeutics stock. Dimensional Fund Advisors LP bought a new stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 11,444 shares of the company’s stock, valued at approximately $33,000. Dimensional Fund Advisors LP owned about 0.23% of Tempest Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.